BofA Remains Positive on Travere Despite FDA Decision Delay for Filspari
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now.
Travere Therapeutics Inc. (TVTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Impax Asset Management Ian Simm | 225,000 | $8,597,250 | -53% | 0.05% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.85 | 5,000 | $89,250.00 | 245,556 | 2017-06-14 | Filing | |
| $15.31 | 5,000 | $76,564.50 | 52,000 | 2016-03-04 | Filing | |
| $8.60 | 15,000 | $129,049.50 | 35,000 | 2014-11-25 | Filing | |
| $8.38 | 6,100 | $51,118.00 | 129,165 | 2014-11-21 | Filing | |
| $8.50 | 8,700 | $73,950.00 | 371,756 | 2014-11-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $30.10 | 51,865 | $1,560,980.91 | 419,173 | 2026-01-27 | Filing | |
| $30.01 | 8,135 | $244,153.31 | 419,173 | 2026-01-23 | Filing | |
| $27.34 | 10,000 | $273,420.00 | 90,270 | 2026-01-20 | Filing | |
| $37.75 | 445 | $16,798.75 | 86,311 | 2026-01-06 | Filing | |
| $40.18 | 2,031 | $81,605.58 | 86,756 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,309,229 | $241,075,642 | 0% | |
| 2. | 534,614 | $20,778,288 | 0.02% | |
| 3. | 518,357 | $19,806,421 | 0.03% | |
| 4. | 422,619 | $16,148,272 | 0% | |
| 5. | 417,742 | $15,961,922 | 0.02% |
News See All
14 Best Mid-Cap Growth Stocks to Buy Right Now
On January 8, Nancy Prial, Co-CEO & Senior Portfolio Manager at Essex Investment Management, appeared on CNBC and suggested she sees significant upside in 2026 for undiscovered small- and midcap firms...
Travere Therapeutics (TVTX) Climbs 25% on Impressive Earnings
Travere Therapeutics soared by 25.3 percent week-on-week as investors took heart from a stellar earnings performance and cues that the company would kick off the last month of the year on a strong note...
Travere Therapeutics (TVTX) Hits Fresh High on Impressive Earnings, Bullish Outlook
Travere Therapeutics climbed to a fresh record high on Friday, as investors took heart from a stellar earnings performance and cues that the company would kick off the last month of the year on a strong...
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Travere Therapeutics' Third Quarter 2025 Financial Results Conference Call. Today's call is being recorded.
Travere Therapeutics (TVTX) Skyrockets to Fresh High as FDA Concerns on Drug Candidate Subside
Travere Therapeutics, Inc.
Citi Lifts Travere Therapeutics (TVTX) PT to $34 on Strong Q2 and Upcoming FDA Catalysts
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best small cap stocks with biggest upside potential.
9 Best Small Cap Stocks with Biggest Upside Potential
On August 14, Jonathan Krinsky of BTIG, joined 'Closing Bell' on CNBC to discuss whether the recent rally in small cap stocks is sustainable.
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q2 2025 Earnings Call Transcript
Operator: Good afternoon, and welcome to the Travere Therapeutics Second Quarter 2025 Financial Results Conference Call. Today's call is being recorded.
Leerink Partners Reiterates a Bullish Stance on Travere Therapeutics (TVTX)
Travere Therapeutics, Inc. (NASDAQ:TVTX) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
Hedge Fund Resource Center Billionaire Hedge Funds
